WHAT IS DYSFERLINOPATHY?
LGMD2B/LGMDR2/MIYOSHI MYOPATHY 1
The Jain Foundation is exploring all avenues from the laboratory bench to bedside in the quest of identifying treatments for dysferlinopathy. Our innovative approach supports groundbreaking research, development of resources, diagnostic and educational programs, pre-clinical testing of promising treatments, and the development of tools needed to run successful clinical trials, such as a disease specific registry and outcome measures.
Through the collaborative effort of the many people involved in this effort, Jain Foundation staff, researchers, clinicians, patients, caregivers, regulatory agencies, and industry, we are driving real change for those with dysferlinopathy.
Travel Grant Program
The Jain Foundation is pleased to announce a new program covering travel expenses for researchers to present dysferlin-related research at scientific conferences. Applicants can be principal investigators, postdoctoral fellows, or graduate students at non-profit institutions. The work presented must be focused on dysferlin or dysferlinopathy but does not have to be funded by the Jain Foundation. Grants can be up to $2000 for domestic travel and up to $3000 for international travel.
Travel Grant Program
The Jain Foundation is pleased to announce a new program covering travel expenses for researchers to present dysferlin-related research at scientific conferences. Applicants can be principal investigators, postdoctoral fellows, or graduate students at non-profit institutions. The work presented must be focused on dysferlin or dysferlinopathy but does not have to be funded by the Jain Foundation. Grants can be up to $2000 for domestic travel and up to $3000 for international travel.
MAKING AN IMPACT
FUNDING MISSION CRITICAL PROGRAMS
120+
We carefully select and monitor research projects, studies and other programs to advance our mission
INVESTING
IN THE CURE
$35+M
Over 35 million dollars invested in research, drug development and patient support and education
WORKING TOWARDS
THE FUTURE
COS
Our Clinical Outcome Study (COS) provides critical information for the successful design of clinical trials
PREPARING THE COMMUNITY FOR TRIALS
900+
We have identified over 900 genetically confirmed individuals with dysferlinopathy worldwide
MAKING AN IMPACT
FUNDING MISSION
CRITICAL PROGRAMS
120+
We carefully select and monitor research projects, studies and other programs to advance our mission
INVESTING
IN THE CURE
$35+M
Over 35 million dollars invested in research, drug development and patient support and education
WORKING TOWARDS
THE FUTURE
COS
Our Clinical Outcome Study (COS) provides critical information for the successful design of clinical trials
PREPARING THE COMMUNITY FOR TRIALS
900+
We have identified over 900 genetically confirmed individuals with dysferlinopathy worldwide
MAKING AN IMPACT
FUNDING MISSION CRITICAL PROGRAMS
120+
We carefully select and monitor research projects, studies and other programs to advance our mission
INVESTING
IN THE CURE
$35+M
Over 35 million dollars invested in research, drug development and patient support and education
WORKING TOWARDS
THE FUTURE
COS
Our Clinical Outcome Study (COS) provides critical information for the successful design of clinical trials
PREPARING THE COMMUNITY FOR TRIALS
900+
We have identified over 900 genetically confirmed individuals with dysferlinopathy worldwide